Why the study?
Cardiac involvement is a prominent extramuscular manifestation in anti-SRP immune-mediated necrotizing myopathy, but sufficient cardiac magnetic resonance imaging data are lacking.
Case Report (n=1)
No
Serial cardiac magnetic resonance imaging can noninvasively identify myocardial edema and inflammation and quantitatively monitor treatment response to B-cell depleting therapy in patients with anti-SRP immune-mediated necrotizing myopathy presenting with severe cardiac involvement.
Answers are grounded in this paper and cite their sources.
Serial CMR may monitor B-cell depletion response in anti-SRP myopathy with cardiac involvement; leaves open need for controlled trials before adoption.
Immune-mediated necrotising myopathy (IMNM) is a rare autoimmune disease recently recognised as part of the spectrum of idiopathic inflammatory myopathies. Although cardiac involvement is a prominent extramuscular manifestation in anti-signal recognition particle (SRP) IMNM, there remains a lack of sufficient cardiac magnetic resonance imaging data. Here, we present a case of anti-SRP IMNM with cardiac involvement as the initial symptom, utilising imaging assessments at various stages of the disease to evaluate and monitor disease progression and treatment response. These findings may provide valuable insights for the clinical identification and management of anti-SRP IMNM with cardiac involvement.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) conducted a case report in Anti-signal recognition particle (SRP) immune-mediated necrotizing myopathy (IMNM) with cardiac involvement (n=1). Sacubitril/valsartan, rituximab, and ofatumumab was evaluated on Myocardial enhancement volume on late gadolinium enhancement (LGE) cardiac magnetic resonance imaging.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: